Transcatheter Aortic Valve Replacement With the Latest-Iteration Self-Expanding or Balloon-Expandable Valves DOI Creative Commons
Giuliano Costa, Francesco Saia, Thomas Pilgrim

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2022, Volume and Issue: 15(23), P. 2398 - 2407

Published: Sept. 16, 2022

Language: Английский

Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial DOI Open Access
Duk‐Woo Park, Jung‐Min Ahn, Do‐Yoon Kang

et al.

Circulation, Journal Year: 2022, Volume and Issue: 146(6), P. 466 - 479

Published: April 4, 2022

Background: It is unknown whether the direct oral anticoagulant edoxaban can reduce leaflet thrombosis and accompanying cerebral thromboembolic risk after transcatheter aortic valve replacement. In addition, causal relationship of subclinical with thromboembolism neurological or neurocognitive dysfunction remains unclear. Methods: We conducted a multicenter, open-label randomized trial comparing dual antiplatelet therapy (aspirin plus clopidogrel) in patients who had undergone successful replacement did not have an indication for anticoagulation. The primary end point was incidence on 4-dimensional computed tomography at 6 months. Key secondary points were number volume new lesions brain magnetic resonance imaging serial changes function between months immediately Results: A total 229 included final intention-to-treat population. There trend toward lower group compared (9.8% versus 18.4%; absolute difference, −8.5% [95% CI, −17.8% to 0.8%]; P =0.076). percentage (edoxaban therapy, 25.0% 20.2%; 4.8%; 95% −6.4% 16.0%) median lesion different 2 groups. percentages worsening any major bleeding events found no significant association presence extent change function. Conclusions: without long-term anticoagulation replacement, numerically than but this statistically significant. effects also Because study underpowered, results should be considered hypothesis generating, highlighting need further research. Registration: URL: https://www.clinicaltrials.gov . Unique identifier: NCT03284827.

Language: Английский

Citations

67
Long-Term Follow-Up of Hypoattenuated Leaflet Thickening After Transcatheter Aortic Valve Replacement DOI Creative Commons
Manuel Hein,

Simon Schoechlin,

U Schulz

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2022, Volume and Issue: 15(11), P. 1113 - 1122

Published: June 1, 2022

Language: Английский

Citations

60
Transcatheter Aortic Valve Replacement in Failed Transcatheter Bioprosthetic Valves DOI Creative Commons
Giuseppe Tarantini, Janarthanan Sathananthan, Tommaso Fabris

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2022, Volume and Issue: 15(18), P. 1777 - 1793

Published: Sept. 1, 2022

Language: Английский

Citations

56
Balloon- vs Self-Expanding Valve Systems for Failed Small Surgical Aortic Valve Bioprostheses DOI Creative Commons
Josep Rodés‐Cabau, Amr E. Abbas, Violeta Serra

et al.

Journal of the American College of Cardiology, Journal Year: 2022, Volume and Issue: 80(7), P. 681 - 693

Published: May 18, 2022

Language: Английский

Citations

48
Transcatheter Aortic Valve Replacement With the Latest-Iteration Self-Expanding or Balloon-Expandable Valves DOI Creative Commons
Giuliano Costa, Francesco Saia, Thomas Pilgrim

et al.

КАРДИОЛОГИЯ УЗБЕКИСТАНА, Journal Year: 2022, Volume and Issue: 15(23), P. 2398 - 2407

Published: Sept. 16, 2022

Language: Английский

Citations

46